Agenzia Italiana del Farmaco
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis - COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis
The Italian Medicines Agency would like to inform you of the following:
- Cases of myocarditis and pericarditis have been reported very rarely following vaccination with the COVID-19 mRNA Vaccines Comirnaty and Spikevax.
- The cases primarily occurred within 14 days after vaccination, more often after the second dose and in younger men.
- Available data suggest that the course of myocarditis and pericarditis following vaccination is similar to the course of myocarditis and pericarditis in general.
- Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.
- Healthcare professionals should advise vaccinated individuals to seek immediate medical attention should they experience chest pain, shortness of breath, or palpitations.
Published on: 19 July 2021
💊 Farmacovigilanza attiva: bando per progetto nazionale dedicato a #pazienti anziani, multicronici ...
Vai al post →
From across Europe to Rome to discuss #OrphanMedicines and #RareDiseases
The meeting of the Committ...
Vai al post →
📍AIFA partecipa alla nona edizione dei Seminari di Mogliano Veneto
Due giornate di confronto sull’...
Vai al post →
📢 Il CdA di #AIFA dà il via libera alla rimborsabilità di 2 nuovi #farmaci orfani per il trattament...
Vai al post →
Da tutta Europa a Roma per parlare di #farmaci orfani e malattie rare.
📍 In corso il meeting del C...
Vai al post →
💊 Quando un farmaco manca in farmacia per problemi distributivi
AIFA, @assofarm, @farmacieunite e ...
Vai al post →
